Stocktoria
Disc Medicine, Inc. IRON
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-08-12
Disc Medicine, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $170.6M | $96.7M | $69.3M | $33.4M | $25.2M |
| SG&A expense | $65.4M | $33.0M | $21.9M | — | — |
| Operating income | -$236.0M | -$129.7M | -$91.1M | -$47.5M | -$30.9M |
| Interest expense | — | — | — | — | $2.2M |
| Income tax | $361,000 | $355,000 | $99,000 | $0 | — |
| Net income | -$212.2M | -$109.4M | -$76.4M | -$46.8M | -$36.0M |
| EPS (diluted) | $-6.01 | $-3.96 | $-3.42 | $-45.05 | $-40.95 |
| Operating cash flow | -$180.4M | -$93.9M | -$73.5M | -$42.3M | -$27.5M |
| Free cash flow | -$181.3M | -$94.4M | -$73.6M | -$42.4M | -$27.6M |
| Cash & equivalents | $91.1M | $192.4M | $360.4M | $194.6M | $88.0M |
| Total assets | $806.9M | $496.8M | $368.0M | $200.2M | $92.4M |
| Total liabilities | $67.1M | $53.2M | $22.9M | $23.6M | $14.8M |
| Shareholders' equity | $739.8M | $443.6M | $345.1M | $176.6M | -$64.2M |
Source: SEC EDGAR filings · CIK 0001816736 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.